CRC Research Update

  • TRIAL DATA

    Phase III Trial Compares Total Neoadjuvant Therapy Approaches in High-Risk Rectal Cancer

    A multicenter, randomized phase III trial evaluated total neoadjuvant therapy with long-course radiotherapy versus chemoradiotherapy in patients with high-risk locally advanced rectal cancer. (Journal of Clinical Oncology)

  • SCREENING

    Study Assesses New FIT Buffer for Hemoglobin Preservation

    A study assessed the faecal hemoglobin preservation capacity of a new faecal immunochemical test buffer formulation (SOC4) at varying temperatures and storage times. Fresh faecal samples were collected using buffers containing either the standard (SOC3) or new formulation (SOC4). (Journal of Clinical Laboratory Analysis)

  • LIVING WITH CRC

    Real-World Study Examines Immune-Related Side Effects in Neoadjuvant Immunotherapy

    A multicenter study of 452 colorectal cancer patients who received neoadjuvant immunotherapy analyzed the incidence of immune-related adverse events and perioperative outcomes following curative surgery. (Zhonghua Wei Chang Wai Ke Za Zhi)

  • RESEARCH

    PLOD2 Protein Linked to Tumor Growth in Colorectal Cancer

    Preclinical research using single-cell RNA sequencing found that PLOD2, often overexpressed in colorectal cancer, has been implicated in promoting tumor growth and epithelial-mesenchymal transition. Functional assays in CRC cell lines with PLOD2 knockdown showed a reduction in proliferation, migration, and EMT markers, along with increased apoptosis. (International Immunopharmacology)

🔬 Under 50 Spotlight

Research relevant to early-onset and younger CRC patients

These findings continue to advance our understanding of colorectal cancer treatment and care across all stages of the disease.